• Sodium Nitroprusside and Sex-Specific Vascular Research

  2026-10-13

  A source-grounded overview of how nitric oxide signaling relates conceptually to sex differences in angiotensin II–induced hypertension, while distinguishing documented findings from supplier claims and identifying key applicability limits.

• 5-Azacytidine and Gastric Cancer Epigenetics

  2026-10-13

  The supplied evidence supports a mechanistic model in which Helicobacter pylori infection is associated with HNF4A promoter hypermethylation, reduced HNF4A expression, disrupted epithelial polarity, and activation of EMT-related signaling in gastric cancer models. However, the cited study does not establish that 5-Azacytidine was used, nor does it show that a DNA demethylation agent would prevent or reverse these outcomes in patients.

• HBsAg, TBK1 and Incomplete Autophagy in HBV

  2026-10-12

  A 2025 Cell Death and Disease study examines how hepatitis B surface antigen may redirect TBK1 signaling to reduce type I interferon responses while promoting incomplete autophagy. The findings support a mechanistic model linking HBsAg, TBK1 dimerization, IRF3 signaling, p62 phosphorylation and SNAP29-related autophagic flux, but the evidence remains bounded by model selection, pharmacologic perturbation and limited clinical context.

• What the H5/H7 mRNA–LNP Study Shows—and Does Not

  2026-10-12

  Wei et al. report broad protective effects of a bivalent mRNA–LNP vaccine in SPF chickens, but the findings remain preclinical and strain-, model-, and endpoint-limited. Br-DAPI is discussed only as a supplier-described DNA-binding fluorescence product; it was not reported as part of the cited vaccine study.

• Ranolazine Beyond Cardiac Ischemia: Evidence Map

  2026-10-10

  Ranolazine is best known as an anti-ischemic agent, but its metabolic actions raise carefully bounded questions for liver and HBV biology. This evidence map connects cardiac mechanism, hepatic metabolism, and the HBsAg–TBK1–autophagy findings without overstating an unproven antiviral effect.

• Anlotinib in IADSRCT: Case Evidence

  2026-10-09

  Chen and Feng reported the first published case of metastatic intra-abdominal desmoplastic small round cell tumor showing radiographic lymph-node reduction during anlotinib treatment. The finding is clinically interesting but hypothesis-generating: it supports further study of multi-target anti-angiogenic therapy without establishing efficacy or a standard treatment approach.

• Prestained Protein Marker F4005: Product Overview

  2026-10-09

  APExBIO’s F4005 is a triple-color protein ladder spanning 10–250 kDa. The supplier describes it as a visible molecular-weight reference for SDS-PAGE separation monitoring and Western blot transfer assessment. No matched paper evidence is available.

• D-Luciferin Sodium Salt for Bioluminescence

  2026-10-08

  D-Luciferin sodium salt is a firefly luciferase substrate for ATP-dependent bioluminescence assays and reporter-based imaging. It can support cell viability and metabolism monitoring, but its light output is a composite readout rather than a direct measure of tumor response or CAR-macrophage activity.

• Latrunculin B and Reovirus Entry: Evidence Review

  2026-10-08

  This source-grounded overview examines what latrunculin B can and cannot show about actin-dependent viral entry. It places the 2018 grass carp reovirus inhibitor study in context, compares the evidence for clathrin-mediated uptake with the negative latrunculin B result, and explains limitations affecting interpretation and broader applicability.

• SM-164: Evidence, Mechanism, and Limitations

  2026-10-07

  A source-grounded overview of SM-164 as a bivalent Smac mimetic, covering its proposed IAP-targeting principle, reported apoptosis findings, evidence quality, interpretation of caspase and tumor-response data, and the limits of extrapolating supplier claims or a separate Pol II preprint to broader cancer research.

• PBS (Phosphate-Buffered Saline) Product Overview

  2026-10-07

  PBS (Phosphate-Buffered Saline), SKU K2818, is described by APExBIO as a sterile aqueous buffer for routine in vitro research applications. No matched paper evidence was provided, so documented product specifications should not be interpreted as independent performance validation.

• AG-221 (Enasidenib): From 2-HG to Causal Biology

  2026-10-06

  AG-221 (Enasidenib) offers a mechanistic lens for studying IDH2-mutant AML beyond simple cytotoxicity. This article connects 2-hydroxyglutarate reduction with CD44-dependent metabolic rewiring and shows how evidence can be interpreted across molecular, cellular, and translational levels.

• Toremifene Citrate: Evidence, Scope and Limits

  2026-10-06

  A source-grounded overview of Toremifene Citrate, covering its SERM principles, clinical and preclinical evidence, interpretation of estrogen receptor findings, applicability boundaries, and important limitations.

• RNA Pol II Inhibition and Active Cell Death Signaling

  2026-10-05

  Harper et al. show that RNA polymerase II inhibition can trigger apoptosis through active sensing of hypophosphorylated RNA Pol IIA, rather than through transcriptional failure and passive mRNA decay alone. Their PDAR framework links RNA Pol II degradation to mitochondrial death signaling and helps explain why mechanistically diverse anticancer compounds can share a common lethal response.

• Actinomycin D: A Lens on RNA Stress

  2026-10-04

  Actinomycin D is more than a transcriptional inhibitor: it can serve as an interpretive probe for separating RNA production, stability, and stress responses. This article examines its relevance to circRNA-mediated cardioprotection while defining the evidence limits that distinguish mechanistic insight from experimental overreach.

544 records 1/37 page Next 12345 下5页 Last page